Drug intelligence / Profile preview

3-(2-AMINO-6-BENZOYLQUINAZOLIN-3(4H)-YL)-N-CYCLOHEXYL-N-METHYLPROPANAMIDE

Development stage: Unknown
Modality: Small Molecules

Overview

This compound is an experimental small molecule, likely investigated for its potential in inhibiting beta-secretase 1, given its structural similarity to compounds targeting this enzyme. Beta-secretase 1 is involved in the proteolytic processing of amyloid precursor protein (APP), a key step in the formation of amyloid-beta peptides associated with Alzheimer's disease. However, specific details about its mechanism of action or development status are not provided in the available data.

Targets

BACE1 (Beta-site APP-cleaving enzyme 1)

Beyond the preview

Go deeper on 3-(2-AMINO-6-BENZOYLQUINAZOLIN-3(4H)-YL)-N-CYCLOHEXYL-N-METHYLPROPANAMIDE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3-(2-AMINO-6-BENZOYLQUINAZOLIN-3(4H)-YL)-N-CYCLOHEXYL-N-METHYLPROPANAMIDE.

Explore the full profile